Published in Clin J Am Soc Nephrol on March 04, 2009
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med (2013) 3.83
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int (2015) 1.50
Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int (2010) 1.38
Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease. J Hypertens (2010) 1.22
Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis (2010) 1.04
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis (2013) 1.01
Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant (2011) 1.00
Quality of life of patients with ADPKD-Toranomon PKD QOL study: cross-sectional study. BMC Nephrol (2013) 0.90
Evaluation and management of pain in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis (2010) 0.86
A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant (2014) 0.82
Growth of arachnoid cysts in patients with autosomal dominant polycystic kidney disease: serial imaging and clinical relevance. Clin Kidney J (2012) 0.75
Understanding the physical and emotional impact of early-stage ADPKD: experiences and perspectives of patients and physicians. Clin Kidney J (2015) 0.75
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Autosomal dominant polycystic kidney disease. N Engl J Med (1993) 5.64
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med (1996) 5.46
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet (1994) 3.73
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis (2003) 2.18
Physical symptoms and quality of life in patients on chronic dialysis: results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD) Nephrol Dial Transplant (1999) 2.04
Increased systolic pressure in chronic uremia. Role of arterial wave reflections. Hypertension (1992) 1.78
Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2003) 1.72
Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther (2002) 1.67
Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol (2002) 1.63
Quality-of-life evaluation using Short Form 36: comparison in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis (2000) 1.60
Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol (1995) 1.58
Health-related quality of life in dialysis patients. A report from an Italian study using the SF-36 Health Survey. DIA-QOL Group. Nephrol Dial Transplant (1999) 1.57
Impact of Huntington's disease on quality of life. Mov Disord (2001) 1.37
Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis (1992) 1.33
Pain management in polycystic kidney disease. Kidney Int (2001) 1.31
Health-related quality of life in Australian adults with renal insufficiency: a population-based study. Am J Kidney Dis (2003) 1.24
Nutritional status affects quality of life in Hemodialysis (HEMO) Study patients at baseline. J Ren Nutr (2002) 1.23
Cross-sectional study of health-related quality of life in African Americans with chronic renal insufficiency: the African American Study of Kidney Disease and Hypertension Trial. Am J Kidney Dis (2002) 1.15
Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients. AJR Am J Roentgenol (1992) 0.99
Impact of socioeconomic status on the quality of life of ESRD patients. Am J Kidney Dis (2003) 0.94
Investigating correlates of health related quality of life in a low-income sample of patients with diabetes. Qual Life Res (2002) 0.84
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension (2012) 2.86
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J (2004) 2.25
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J (2009) 2.12
The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease. Eur Heart J (2010) 2.04
Post-traumatic stress disorder and incidence of coronary heart disease: a twin study. J Am Coll Cardiol (2013) 2.03
The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol (2013) 1.97
The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol (2011) 1.96
Timing of dialysis initiation and survival in ESRD. Clin J Am Soc Nephrol (2010) 1.94
Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol (2002) 1.93
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
Patient literacy and question-asking behavior during the medical encounter: a mixed-methods analysis. J Gen Intern Med (2007) 1.88
Incidental findings of thickening luminal gastrointestinal organs on computed tomography: an absolute indication for endoscopy. Am J Gastroenterol (2003) 1.87
Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation (2002) 1.85
Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J Am Coll Cardiol (2013) 1.77
Mohs micrographic surgery vs traditional surgical excision: a cost comparison analysis. Arch Dermatol (2004) 1.75
Coronary stent restenosis in patients treated with cilostazol. Circulation (2005) 1.73
Heritability and seasonal variability of vitamin D concentrations in male twins. Am J Clin Nutr (2010) 1.73
Factors affecting resident career decisions: the first five years of the society for investigative dermatology resident retreat. J Invest Dermatol (2010) 1.67
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension (2008) 1.66
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol (2011) 1.63
Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. J Am Coll Cardiol (2012) 1.63
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension (2012) 1.59
Cystic and inherited kidney diseases. Am J Kidney Dis (2003) 1.59
Comparison of diagnostic and management sensitivity to melanoma between dermatologists and MelaFind: a pilot study. Arch Dermatol (2012) 1.58
Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int (2008) 1.58
Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol (2010) 1.57
Quantitative and comparative assessment of learning in a tongue-operated computer input device. IEEE Trans Inf Technol Biomed (2011) 1.57
The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic. J Am Acad Dermatol (2007) 1.56
Influence of sex on risk stratification with stress myocardial perfusion Rb-82 positron emission tomography: Results from the PET (Positron Emission Tomography) Prognosis Multicenter Registry. J Am Coll Cardiol (2013) 1.54
Association of a genetic risk score with prevalent and incident myocardial infarction in subjects undergoing coronary angiography. Circ Cardiovasc Genet (2012) 1.54
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2006) 1.53
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet (2012) 1.52
Adherence to the mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study. Circulation (2007) 1.51
Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. Am J Nephrol (2013) 1.50
Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis (2005) 1.49
Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention. J Interv Cardiol (2009) 1.47
Acute abdominal pain: value of non-contrast enhanced ultra-low-dose multi-detector row CT as a substitute for abdominal radiographs. Emerg Radiol (2008) 1.47
Effects of targeted papillary muscle relocation on mitral leaflet tenting and coaptation. Ann Thorac Surg (2012) 1.46
Prognostic significance of impaired chronotropic response to pharmacologic stress Rb-82 PET. J Nucl Cardiol (2014) 1.46
Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int (2003) 1.45
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens (2015) 1.43
Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens (2008) 1.41
Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes (2008) 1.40
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis (2011) 1.39
Baseline fractional flow reserve and stent diameter predict optimal post-stent fractional flow reserve and major adverse cardiac events after bare-metal stent deployment. JACC Cardiovasc Interv (2009) 1.39
Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol (2005) 1.38
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol (2006) 1.37
Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry (2008) 1.27
MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol (2009) 1.24
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.21
WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension (2005) 1.18
Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2008) 1.18
Early trauma and inflammation: role of familial factors in a study of twins. Psychosom Med (2012) 1.15
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension (2009) 1.15
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension (2013) 1.14
Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int (2011) 1.13
Dialysis at a crossroads: 50 years later. Clin J Am Soc Nephrol (2010) 1.13
Melanoma outcomes for Medicare patients: association of stage and survival with detection by a dermatologist vs a nondermatologist. Arch Dermatol (2007) 1.13
Screening for chronic kidney disease: unresolved issues. J Am Soc Nephrol (2003) 1.13
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One (2013) 1.12
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics (2011) 1.12
Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation. J Am Coll Cardiol (2002) 1.11
Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One (2013) 1.10
Quantitative and comparative assessment of learning in a tongue-operated computer input device--part II: navigation tasks. IEEE Trans Inf Technol Biomed (2012) 1.10
Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens (2003) 1.09
Posttraumatic stress disorder and impaired autonomic modulation in male twins. Biol Psychiatry (2013) 1.08
Reduced renal function in patients with simple renal cysts. Kidney Int (2004) 1.08
Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens (2005) 1.08
Is heart rate variability related to memory performance in middle-aged men? Psychosom Med (2011) 1.07
Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging (2010) 1.06
Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis (2010) 1.04
Localized cystic disease of the kidney: an unusual entity that can mimic a cystic neoplasm. Am J Kidney Dis (2009) 1.04
Ultrasonography in renal transplantation. Am J Kidney Dis (2002) 1.04
Controversies in renal artery stenosis: a review by the American Society of Nephrology Advisory Group on Hypertension. Am J Nephrol (2007) 1.02
Determinants and functional significance of renal parenchymal volume in adults. Clin J Am Soc Nephrol (2010) 1.02
Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data. Arch Dermatol (2010) 1.02
Association between gender and in-hospital mortality after percutaneous coronary intervention according to age. Am J Cardiol (2003) 1.01
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol (2005) 1.01
Association between posttraumatic stress disorder and inflammation: a twin study. Brain Behav Immun (2013) 0.99
Features of portal hypertension are associated with major adverse events in Fontan patients: the VAST study. Int J Cardiol (2013) 0.98
Depression and history of attempted suicide as risk factors for heart disease mortality in young individuals. Arch Gen Psychiatry (2011) 0.98